Basel, 28 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced European Medicines Agency (EMA) approval of a new, shorter two-hour OCREVUS® (ocrelizumab) infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis (MS). The approval is based on a positive opinion from the EMA’s Committee for Medicinal Products for Human... Read more
Basel, 28 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc. Read more
Basel, 27 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice,... Read more
Genomics insights generated through sequencing an individual’s DNA play a critical role in personalised healthcare and clinical diagnostics of the future Roche is committed to developing a nanopore sequencer with the aim of providing the healthcare community and ultimately patients with faster and more accurate medical information to predict risk and detect disease This investment... Read more
Pooled data from two pivotal Phase III open-label extension (OLE) studies show satralizumab was well-tolerated as a monotherapy or in combination with baseline immunosuppressive therapy in people with neuromyelitis optica spectrum disorder (NMOSD) Adolescents treated with the same dosing and frequency demonstrated a benefit-risk profile generally consistent with the adult population Current dosing achieved sustained... Read more
Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the US Approval based on the Phase III IMpower110 study showing Tecentriq demonstrated a significant overall survival benefit in people with high PD-L1 expression compared with chemotherapy Basel, 19 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY)... Read more
Roche v-TAC is a new digital diagnostics solution that allows clinicians to obtain arterial blood gas values from patients in need of blood gas testing via a simpler, less painful and less invasive venous method Roche’s new digital tool could help simplify the screening, diagnosis and monitoring of patients with respiratory compromise in the current... Read more
Phase II CITYSCAPE trial shows promising results adding tiragolumab to Tecentriq in people with PD-L1-positive metastatic non-small cell lung cancer Full results will be presented in an oral abstract session at the ASCO20 Virtual Scientific Program organised by the American Society of Clinical Oncology (ASCO) Basel, 14 May 2020 – Roche (SIX: RO, ROG; OTCQX:... Read more
Basel, 11 Mai 2020 – On May 10th 2020 Dr. h.c. Fritz Gerber died in his 92nd year. For more than two decades, he had shaped Roche’s development into a leading global healthcare company in an exceptionally successful dual role as Group CEO (1978-1998) and Chairman of the Board (1978-2001). He remained closely associated with... Read more
Basel, 11 May 2020 Roche today announced that Michael Varney (1958) Ph.D., and Head of Genentech Research and Early Development (gRED) since 2015, will retire from the company at the end of July. Aviv Regev (1971), Ph.D., and currently Chair of the Faculty, Core Institute Member, and member of the Executive Leadership Team of the... Read more